ReviewNutrients2024
Postbiotics as Molecules Targeting Cellular Events of Aging Brain-The Role in Pathogenesis, Prophylaxis and Treatment of Neurodegenerative Diseases.
Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Postbiotics as a therapeutic frontier in Parkinson's disease: Insights into molecular pathways and neuroprotective effects.Metabolic brain disease · 2026Review
- Postbiotics in Functional Foods: Preparation-Based Characterization, Gut-Brain Axis Interactions, and Translational Perspectives.Foods (Basel, Switzerland) · 2026Review
- The Role of Polyphenols on Cognitive Function and Dementia Through Gut-Microbiota-Brain Axis Modulation: A Narrative Review.Nutrients · 2026Review
- Combined Effect ofFoods (Basel, Switzerland) · 2026Article
- Depression in Autism Spectrum Disorder: Neurobiological Convergence and Emerging Therapeutic Strategies.Biology · 2026Review
- Astaxanthin protects human astrocytes (HA) against 6-hydroxydopamine-induced oxidative toxicity.Neurogenetics · 2026Article
- Spermidine in the aging brain: mechanisms, preclinical evidence, and clinical perspectives.Molecular biology reports · 2026Review
- Postbiotics as a Therapeutic Tool in Depression: Exploring into Molecular Pathways and Neuroprotective Effects.Probiotics and antimicrobial proteins · 2026Review
- Prebiotics, Probiotics, and Postbiotics in Modulating Gut Microbiota: Emerging Therapeutic Approaches for Metabolic Syndrome.Current obesity reports · 2026Review
- Article
- Causal Effects Between Neurodegenerative Diseases, Metabolites, and Brain Volume.Current Alzheimer research · 2026Article
- Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects.International journal of nanomedicine · 2026Review
- Role of gut microbiome in suppression of cancers.Gut microbes · 2025Review
- Article
- "Rewiring brain immunity: targeting microglial metabolism for neuroprotection in neurodegenerative disorders".Metabolic brain disease · 2025Review
- Gut Microbiome as a Source of Probiotic Drugs for Parkinson's Disease.International journal of molecular sciences · 2025Review
- Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders.Cells · 2025Review
- Nutritional Interventions in Amyotrophic Lateral Sclerosis: From Ketogenic Diet and Neuroprotective Nutrients to the Microbiota-Gut-Brain Axis Regulation.Molecular neurobiology · 2025Review
- Microbiome Engineering for Biotherapeutic in Alzheimer's Disease Through the Gut-Brain Axis: Potentials and Limitations.International journal of molecular sciences · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is the most prominent risk factor for neurodegeneration occurrence. The most common neurodegenerative diseases (NDs), Alzheimer's (AD) and Parkinson's (PD) diseases, are characterized by the incidence of proteinopathy, abnormal activation of glial cells, oxidative stress, neuroinflammation, impaired autophagy and cellular senescence excessive for the patient's age. Moreover, mitochondrial disfunction, epigenetic alterations and neurogenesis inhibition, together with increased blood-brain barrier permeability and gut dysbiosis, have been linked to ND pathogenesis. Since NDs still lack curative treatment, recent research has sought therapeutic options in restoring gut microbiota and supplementing probiotic bacteria-derived metabolites with beneficial action to the host-so called postbiotics. The current review focuses on literature explaining cellular mechanisms involved in ND pathogenesis and research addressing the impact that postbiotics as a whole mixture and particular metabolites, such as short-chain fatty acids (SCFAs), lactate, polyamines, polyphenols, tryptophan metabolites, exopolysaccharides and bacterial extracellular vesicles, have on the ageing-associated processes underlying ND occurrence. The review also discusses the issue of implementing postbiotics into ND prophylaxis and therapy, depicting them as compounds addressing senescence-triggered dysfunctions that are worth translating from bench to pharmaceutical market in response to "silver consumers" demands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.